Please login to the form below

Not currently logged in

BMS' myeloma treatment accepted for priority review

If approved elotuzumab will be marketed as Empliciti
Bristol-Myers Squibb Building

Bristol-Myers Squibb's drug elotuzumab has been granted priority review by the FDA as a combination therapy for the treatment of blood cancer.

The decision means that elotuzumab has taken a big step towards US approval, as regulators will now review its marketing application in just six months. 

If the drug is approved, BMS plans to market it under the brand name Empliciti. 

The FDA's decision to expedite its review process comes on the back of early data in the Eloquent-2 clinical trial involving 646 patients published in The New England Journal of Medicine.

The results showed that adding elotuzumab to treatment with Celgene's Revlimid (lenalidomide) and dexamethasone cut the risk of the disease progressing by 30% and additionally extended remission by over four months. 

The drug was also evaluated in a phase II trial that showed adding elotuzumab to Johnson and Johnson's Velcade (bortezomib) and dexamethasone improved median progression free survival rates by nearly three months.

Michael Giordano, senior VP and head of oncology development at BMS, said: “Bristol-Myers Squibb is delighted by the approach both agencies have taken to review the Empliciti applications as it underscores the unmet medical need in the treatment of multiple myeloma.”

BMS is co-developing elotuzumab with AbbVie, but their collaboration sees BMS solely responsible for all commercial activities.

Elotuzumab was designated 'breakthrough' drug by the FDA last year, which is designed to accelerate development and review of treatments for life-threatening conditions.

Analysts have suggested the drug could reach $300m peak sales. The myeloma market was valued at $7.3bn in 2014 and is set to expand to just under $9bn by 2021. 

Despite various advances in multiple myeloma treatment, the disease is largely incurable and only 45% of patients survive past five years after diagnosis. 

Article by
Nikhil Patel

3rd September 2015

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Securing a future for telehealth with immersive market research insights...